Sun-Novo: BTP4507 has received the notification of approval for clinical trials
I'm PortAI, I can summarize articles.
According to the Zhitong Finance APP, Sun-Novo announced that its subsidiary Jiangsu Novo Biotech Co., Ltd. has received the "Drug Clinical Trial Approval Notice" issued by the National Medical Products Administration. The clinical trial application for the company's research project BTP4507 has been approved. BTP4507 is intended for the treatment of patients with primary hypertension who have poor response to monotherapy
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments